[quick news] on August 10, 2018, zero tariff of anticancer drugs reached 100 days: multiple departments urged the price reduction of "life-saving drugs"

Zero tariff for anti-cancer drugs for 100 days: many departments have pushed for the price reduction of "life-saving drugs" It is reported that since May 1 this year, China has implemented "zero tariff" for anti-cancer drugs and other drugs for 100 days Over the past three months, we have worked together in many areas, departments and measures to promote people's access to and use of "life-saving drugs" through medical insurance access negotiations, provincial-level anti-cancer drug special centralized procurement, accelerating the approval process of overseas new drugs, including medical insurance and other measures Http:// new progress has been made in the research of metal nanoclusters Recently, Yang Xueming and Ma Zhibo of Dalian Institute of chemical technology of Chinese Academy of Sciences, together with Zheng Nanfeng and Hannu Hakkinen of Xiamen University and Hannu Hakkinen of University of Weasley, Finland, have passed the STM ）The surface ligands of Ag 374 nanoclusters with well-known atomic structure were studied to obtain super-high resolution at the sub molecular level Combined with DFT theoretical calculation and template recognition algorithm, the morphology, structure and cluster orientation of the surface ligands were identified Http://news.scienceet.cn/htmlnews/2018/8/416367.shtm the 24th international pattern recognition conference will be held in China The 24th international pattern recognition conference will be held in Beijing from August 20 to 24, which is the first time that it has been held in mainland China for more than 40 years This conference is sponsored by the international pattern recognition Federation, Chinese society of automation and Institute of automation of Chinese Academy of Sciences At that time, famous experts in pattern recognition, machine learning, computer vision and other related fields at home and abroad will gather together to exchange the latest achievements and development trends in related research fields Http://news.scienceet.cn/htmlnews/2018/8/416369.shtm new lymphoma drug poteligeo was approved by FDA recently, FDA announced that poteligeo (mogalilizumab kpkckc) had been approved to be on the market, and the treatment of relapsed or refractory mycosis mycoides (MF) or Sezary syndrome which had received at least one systemic treatment, SS) adult patients This is the first time that FDA has approved drugs for SS, and it also provides more treatment options for MF patients Https:// recently reported that quizatinib, the first trimester leukaemia drug, has obtained the breakthrough treatment qualification pmlive Japan's first trimester leukaemia drug is starting to submit the listing application of quizatinib, an acute myeloid leukemia (AML) drug, to the U.S FDA The grant of the drug's breakthrough treatment qualification may allow it to be approved more quickly The breakthrough therapy qualification enables DS to work more closely with FDA to get approval of the drug more quickly This qualification is based on the data of a three-stage trial, which shows that quizatinib prolongs the life span of AML patients with flt3-itd mutation http://